Table 4.
Clinical and Laboratory Features of the Patients Seronegative and Seropositive for AQP4 Antibodies Based on the ELISA‐AQP4
| ELISA‐AQP4 (‐) | ELISA‐AQP4 (+) | ||
|---|---|---|---|
| (n = 110) | (n = 14) | P‐value | |
| Female | 54 (49.1%)a | 13 (92.9%) | 0.002 |
| Age (mean ± SD) | 49 ± 17 | 44 ± 14 | ns |
| Neuromyelitis optica (NMO) | 4 (3.6%) | 5 (35.7%) | <0.001 |
| NMO spectrum disorders | 43 (39.1%) | 11 (78.6%) | 0.008 |
| Multiple sclerosis | 7 (6.4%) | 3 (21.4%) | ns |
| Optico‐spinal multiple sclerosis | 0 (0%) | 2 (100%) | 0.012 |
| Optic neuritis | 34 (30.9%) | 11 (78.6%) | 0.001 |
| Transverse myelitis | 20 (18.2%) | 8 (57.1%) | 0.001 |
| Longitudinal extended spinal cord lesion | 6 (5.5%) | 6 (42.9%) | <0.001 |
| Brain MRI lesion compatible with inflammatory demyelination | 11 (0.1%) | 0 (0%) | ns |
| CSF oligoclonal band | 5 (4.5%) | 0 (0%) | ns |
| Patients with other autoantibodies | 19 (17.3%) | 5 (35.7%) | ns |
a
Number of cases (%)
ns, not significant; CSF, cerebrospinal fluid